FDA OFFICE OF EPIDEMIOLOGY DIRECTOR FAICH MOVING TO BESSELAAR-PACT
Executive Summary
FDA OFFICE OF EPIDEMIOLOGY DIRECTOR FAICH MOVING TO BESSELAAR-PACT as a VP in August. The 47 year-old Faich, MD, who will retire from the agency after 20 years in the Public Health Service, has served as director of the Office of Epidemiology and Biostatistics for six years, where he has coordinated adverse reaction reporting and post-marketing surveillance. FDA has not named a replacement for the position. The agency reportedly has not yet decided whether it will conduct an internal or external search for his successor. Next in line to Faich is the office's deputy director Charles Anello, who has been with agency for 20 years. Prior to coming to FDA, Faich spent two years in the Surgeon General's Office. Before that he performed epidemiological research for the Centers for Disease Control for 12 years. At Besselaar, Faich will be responsible for Phase IV studies and drug safety reviews. Corning Laboratory Science Division subsidiary Besselaar, founded by former Merck exec G.H. Besselaar, acquired PACT (Philadelphia Association for Clinical Trials) in December ("The Pink Sheet" Jan. 1, T&G-10). The new corporation says it conducts Phase I-IV studies for at least half of the top 50 U.S. pharmaceutical manufacturers. The company also maintains offices in Europe, Japan and Australia.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth